Teva Pharmaceutical (TEVA) announced the pricing of its debt offering. The company is offering �1.75B of 0.375% fixed rate senior notes due 2020: 99.644%; �1.50B of 1.125% fixed rate senior notes due 2024: 99.231%; and �0.75B of 1.625% fixed rate senior notes due 2028: 98.898%. Net proceeds of ~$3.96B will help fund its acquisition of Actavis Generics.